Protocol for screening α-synuclein PET tracer candidates in vitro and ex vivo.
Model Organisms
Molecular/Chemical Probes
Neuroscience
Journal
STAR protocols
ISSN: 2666-1667
Titre abrégé: STAR Protoc
Pays: United States
ID NLM: 101769501
Informations de publication
Date de publication:
15 Mar 2024
15 Mar 2024
Historique:
received:
27
09
2023
revised:
03
11
2023
accepted:
04
12
2023
pubmed:
20
12
2023
medline:
20
12
2023
entrez:
20
12
2023
Statut:
ppublish
Résumé
Alpha-synuclein (α-Syn) positron emission tomography (PET) imaging is a valuable approach for diagnosing and monitoring synucleinopathies-related diseases, such as Parkinson disease. Here, we present a protocol for screening potential α-Syn PET tracers using in vitro and ex vivo approaches. We describe steps for employing recombinant pre-formed fibrils and conducting screening procedures on neuronal models, mouse models, and patients' brain tissue sections to assess the specificity and selectivity of the candidate compounds. For complete details on the use and execution of this protocol, please refer to Xiang et al. (2023).
Identifiants
pubmed: 38117656
pii: S2666-1667(23)00755-4
doi: 10.1016/j.xpro.2023.102788
pmc: PMC10770748
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102788Subventions
Organisme : NIA NIH HHS
ID : RF1 AG051538
Pays : United States
Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests K.Y. is a co-founder of Shanghai Braegen Pharmaceuticals, Inc. that licensed the PET tracer patent from Emory University. No data are sponsored by the company.